In vitro pharmacodynamics of a danofloxacin plus colistin combination against multidrug-resistant (MDR) Escherichia coli isolated from animals

Yıl 2019, Cilt: 38 Sayı: 2, 24 - 30, 18.12.2019

Murat Cengiz , Pinar Sahinturk Gulce Hepbostanci Halis Akalin , Songul Sonal

https://doi.org/10.30782/jrvm.587122

Öz

As an alternative antimicrobial combination, danofloxacin+colistin was used for the inhibition of multidrug resistant E. coli. After evaluation of interaction between the drugs by fractional inhibitory concentration tests and time kill assays, antimicrobial activity of the combination was showed by in vitro pharmacodynamics tests (minimum bactericidal concentration and mutant prevention concentration). Post-antibiotic and post-antibiotic sub-MIC effects were also determined in this study. In synergism tests, danofloxacin+colistin was found highly synergistic (%87) against E. coliisolates from animal origin. The combination exerted bactericidal activity against all E. coliisolates and individual bactericidal activity of each compound was lower than the combination. The combination reduced mutant prevention concentration of danofloxacin and colistin up to 32 –fold. Post-antibiotic sub-MIC effects of the combination at all sub-MIC concentrations were significantly longer than the post-antibiotic effects of combination (p< 0.001), danofloxacin (p< 0.001) and colistin (p< 0.001). The results of this study showed that danofloxacin+colistin combination can be reserved as an alternative drug combination against MDR E. coliin veterinary medicine.

Anahtar Kelimeler

Colistin, Danofloxacin, in vitro Pharmacodynamics

Destekleyen Kurum

TUBİTAK

Proje Numarası

TOVAG-110O478, BIDEB-2211

Kaynakça

• Sahinturk P, Arslan E, Buyukcangaz E, et al. High level fluoroquinolone resistance in Escherichia coli isolated from animals in Turkey is due to multiple mechanisms. Turk J Vet Anim Sci. 2016;40:214-218.
• Elemam A, Rahimian J, Doymaz MJ. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. Clin Microbiol. 2010;48(10):3558-3562.
• Betts JW, Phee LM, Hornsey M, Woodford N, Wareham DW. In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2014;58(6):3541–3546.
• Lee H, Roh KH, Hong SG, et al. In vitro synergistic effects of antimicrobial combinations on extensively drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii isolates. Ann Lab Med. 2016;36:138-144.
• D'Souza BB, Padmaraj SR, Rekha PD, Tellis RC, Prabhu S, Pothen P. In vitro synergistic activity of colistin and ceftazidime or ciprofloxacin against multidrug-resistant clinical strains of Pseudomonas aeruginosa. Microb Drug Resist. 2014;20(6):550-554.
• European Medicines Agency. Updated advice on the use of colistin products in animals 3 within the European Union: development of resistance 4 and possible impact on human and animal health. EMA 2016;231573.
• Cassir N, Rolain JM, Broqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol. 2014;5:551.
• Kempf I, Jouy E, Chauvin C. Colistin use and colistin resistance in bacteria from animals. Int J Antimicrob Agents. 2016;48:598–606.
• Cengiz M, Sahinturk P, Sonal S, Buyukcangaz E, Sen A, Arslan E. In vitro bactericidal activity of enrofloxacin against gyrA mutant and qnr-containing Escherichia coli isolates from animals. Vet Rec. 2013;172(18):474.
• Dosler S, Karaaslan E, Gerceker AA. Antibacterial and anti-biofilm activities of melittin and colistin, alone and in combination with antibiotics against Gram-negative bacteria. J Chemother. 2016;28(2):95-103.
• Wei W, Yang H, Hu L, Ye Y, Li J. Activity of levofloxacin in combination with colistin against Acinetobacter baumannii: In vitro and in a Galleria mellonella model. J Microbiol Immunol Infect. 2015;15:1684-1692.
• Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics. Eur J Clin Microbiol. 2003;22(4):203-221.
• Odenholt I. Pharmacodynamic effects of subinhibitory antibiotic concentrations. Int J Antimicrob Agents 2001;17:1-8.
• Bambeke FV, Pages JM, Lee VJ. Inhibitors of bacterial efflux pumps as adjuvants in antibiotic treatments and diagnostic tools for detection of resistance by efflux. Recent Pat Antiinfect Drug Discov. 2006;1:157-175.
• Cengiz M, Sahinturk P. Assessment of synergistic interactions of danofloxacin and orbifloxacin against quinolone-resistant Escherichia coli isolated from animals by the checkerboard and time-kill methods. J Antibiot. 2013;66:629-631.
• Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45(2):433-438.
• Lorian V, ed. In vitro determination of PAE. In: Antibiotics in laboratory medicine 4th ed. Maryland: 1996.
• Doyle ME. Multidrug-resistant pathogens in the food supply. Foodborne Pathog Dis. 2015; 12:261-279.
• Prentice HG, Hann IM, Nazareth B, Paterson P, Bhamra A, Kibbler CC. Oral ciprofloxacin plus colistin: prophylaxis against bacterial infection in neutropenic patients. A strategy for the prevention of emergence of antimicrobial resistance. Br J Haematol. 2001;115(1):46-52.
• Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am. 2009;23(4):791.
• Ganiere JP, Denuault L. Synergistic interactions between cefalexin and kanamycin in Mueller–Hinton broth medium and in milk. J Appl Microbiol. 2009;107:117-125.
• Maaland MG, Mo SS, Schwarz S, Guardabassi L. In vitro assessment of chloramphenicol and florfenicol as second-line antimicrobial agents in dogs. J Vet Pharmacol Ther. 2015;38:443-450.
• Li Y, Zhang Y, Ding H, et al. In vitro susceptibility of four antimicrobials against Riemerella anatipestifer isolates: a comparison of minimum inhibitory concentrations and mutant prevention concentrations for ceftiofur, cefquinome, florfenicol, and tilmicosin. BMC Vet Res. 2016;12:250.
• Credito K, Kosowska-Shick K, McGhee P, Pankush GA, Appelbaum PC. Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against Pneumococci. Antimicrob Agents Chemother. 2010; 54 (2):673-677.
• Zhanel GG, Mayer M, Laing N, Adam HJ. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50(6):2228-2230. 26. Cai Y, Yang J, Kan Q, et al. Mutant prevention concentration of colistin alone and in combination with levofloxacin or tobramycin against multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2012;40(5):477-478.
• Brailes A, Rodríguez-Martínez JM, Velasco C, et al. In Vitro Effect of qnrA1, qnrB1, and qnrS1 Genes on Fluoroquinolone Activity against Isogenic Escherichia coli Isolates with Mutations in gyrA and parC. Antimicrob Agents Chemother. 2010;55:1266-1269.
• Harada K, Shimizu T, Kataoka Y, Takahashi T. Post-antibiotic effect of orbifloxacin against Escherichia coli and Pseudomonas aeruginosa isolates from dogs. Acta Vet Scand. 2012;54:16.
• Plachouras D, Giamarellos-Bourboulis EJ, Kentepozidis N, Baziaka F, Vassiliki K, Giamarellou H. In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2007;57:419-422.
• Guzel CB, Gerceker AA. Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. J Antibiot. 2012;65:83-86.